ash 2022 lba: results from final analysis of alpine - zanubrutinib vs ibrutinib for r/r cll/sll
Published 1 year ago • 517 plays • Length 1:00Download video MP4
Download video MP3
Similar videos
-
2:09
ash highlights in cll: moving towards fixed-duration treatment, the role of mrd & alpine results
-
4:51
hot updates in r/r mcl at ash 2022: data on pirtobrutinib, glofitamab & zilovertamab
-
3:21
ash 2022 lba: results from the ecog-acrin e1910 trial
-
1:48
ash 2022 lba: findings from the alife2 trial
-
2:55
zanubrutinib updates from ash 2019
-
6:09
what were the cll highlights at ash 2020?
-
1:18
hodgkin lymphoma highlights at ash 2022 and future outlooks
-
2:10
day 1 of blincyto
-
6:36
anthony mato: loxo-305 demonstrates efficacy in patients with cll/sll
-
28:37
acute lymphocytic leukemia: overview of latest guidelines in hematological malignancies
-
3:48
impressive data: zanubrutinib for waldenström’s macroglobulinemia
-
1:14
exciting updates in r/r multiple myeloma: highlights at ash 2022
-
2:08
ash highlights: results of the triangle study in mcl
-
0:44
updates at ash in cll: u2
-
0:41
ash 2021 highlights in cml
-
2:26
pivotal findings at ash 2020
-
1:03:39
top myeloma research presented at ash 2022
-
2:41
advancements in aml: an update from ash 2023
-
1:32
aml data at ash 2021 and implications on clinical practice
-
1:55
major study data to look out for from ash 2020
-
1:43
ash 2022: what to look forward to in the field of multiple myeloma